51. Post-thymectomy myasthenia gravis: a case report and systematic review of literature
- Author
-
Adam Maxwell, Gabriel Yiin, Alexandra Rice, and Louise Gurowich
- Subjects
Weakness ,Pediatrics ,medicine.medical_specialty ,Neuromuscular disease ,Thymoma ,medicine.medical_treatment ,Ptosis ,Myasthenia Gravis ,medicine ,Humans ,Receptors, Cholinergic ,Autoantibodies ,Aged, 80 and over ,business.industry ,Correction ,General Medicine ,Thymus Neoplasms ,medicine.disease ,Thymectomy ,Myasthenia gravis ,Pyridostigmine ,Prednisolone ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Myasthenia gravis (MG) is an autoimmune condition affecting the neuromuscular junction characterised by weakness and fatiguability, carrying a high morbidity if treatment is delayed. A clear association with thymoma has led to management with thymectomy as a common practice, but MG presenting post-thymectomy has rarely been reported. We present a case of an 82- year-old woman developing fatigue, ptosis and dysarthria 3 months after thymectomy. After a clinical diagnosis of MG was made, she responded well to prompt treatment with prednisolone and pyridostigmine. Her anti-acetylcholine receptor antibody (anti-AChR) subsequently came back positive. Our systematic review reveals that post-thymectomy MG can be categorised as early-onset or late-onset form with differing aetiology, and demonstrated correlation between preoperative anti-AChR titres and post-thymectomy MG. The postulated mechanisms for post-thymectomy MG centre around long-lasting peripheral autoantibodies. Clinicians should actively look for MG symptoms in thymoma patients and measure anti-AChR preoperatively to aid prognostication.
- Published
- 2023